On Friday, Californias Assembly passed a radical pro-abortion bill that would provide free abortions to all college and university students by a vote of 55-19.

Introduced by Connie Leyva (D-Chino), Senate Bill 24 mandates that all public colleges and universities provide abortion drugs to students up to 10 weeks pregnant for free by 2023. The bill has been sent to Governor Gavin Newsoms desk for his signature.

The state has an interest in ensuring that every pregnant person in California who wants to have an abortion can obtain access to that care as easily and as early in pregnancy as possible, the bill states.

As such, SB 24 requires all student healthcare services clinics on a California State University or University of California campus to offer abortion by medication. It requires the Commission on the Status of Women and Girls to administer the College Student Health Center Sexual and Reproductive Health Preparation Fund, which is established by the bill and funded under the bill.

The bill would continuously appropriate the moneys in that fund to the commission for allocations to each public university student health care services clinic for specified activities in preparation for providing abortion by medication techniques, thereby making an appropriation, it continues.

If it becomes law, the initiative would be funded by nonstate entities, including, but not necessarily limited to, private sector entities and local and federal government agencies, the bill says.

SB 24 affects 34 college campuses, the New York Times reports.

The bill covers medical abortions, which involve taking two pills over two days within the first 10 weeks of pregnancy to bring about a miscarriage. To perform an abortion with medication, doctors use a combination of mifepristone and mioprostol, Newsweek explains. Chemical abortions differ from the morning-after pill in that the morning-after bill provides a high dose of a hormone found in birth control pills that either delay or prevent the release of an egg to avoid fertilization. By contrast, the medical abortion pill offered under SB 24 terminates a confirmed pregnancy.

The bill was opposed not only by pro-life groups, but by colleges and the state finance department, all of whom expressed concerns about the safety and costs associated with the legislation.

Students for Life of America (SFLA) President Kristan Hawkins said, California legislators are recklessly experimenting with students lives and health by advancing a plan to force school health centers to become abortion vendors, pushing chemical abortion pills to force an intentional miscarriage.

These Toilet Bowl Abortions would create havoc on campuses, as girls are sent to their dorm bathrooms to bleed and pass an aborted infant in a toilet, without medical supervision or assistance, Hawkins added.

CBN News notes the FDA has documented at least 4,000 cases of serious adverse events, including more than 1,000 women who required hospitalization after taking the chemical abortion pill covered under this legislation.

These findings say nothing of the significant biological and behavioral effects on women following abortions. A three-year study conducted by Franciscan University of Steubenville psychologists and a medical school professor and Ph.D. student in Chiles Universidad San Sebastin, Conceptin, and published in Frontiers in Neuroscience found pregnancy termination results in negative biological, behavioral, and biochemical effects.

Not only does this put college students in physical danger, but it also increases the financial burden created by the legislation, notes Fresno Pro-Life Future president Bernadette Tasy in a letter campaigning against the legislation.

These women would effectively be getting two abortions how will these numerous follow-up surgical abortions, transportation, and any other expenses due to complications be funded? she said.

Governor Newsoms Department of Finance announced its opposition to SB 24 last month, citing significant costs generated by the measure.

While this bill and its sponsors indicate that private financing would cover all the costs associated with this bill, Finance notes this bill could create future General Fund cost pressures to the extent sufficient private funding cannot be raised to support readiness grants, the costs to comply with this bills requirements exceed the proposed grant funding, or to the extent the UC and CSU incur ongoing costs after January 1, 2023, the Department of Finance reported.

Tasy voiced similar concerns, stating that the appropriations in the bill will not cover the incurred costs, and would eventually force students to pay for the abortion meds their peers obtain on campus.

Leyva introduced a similar bill in 2018, SB 320, which was vetoed by Californias then-Governor Jerry Brown. At the time, Governor Brown said the bill was not necessary, as the services provided under the bill were already widely available. Brown also cited a study sponsored by the bills supporters that found the average distance to abortion providers in campus communities varies from five to seven miles, which Brown remarked was not an unreasonable distance.

Following Browns veto, Leyva vowed to reintroduce the bill under the next governor. As the Trump Administration continues to unravel many of the critical health care protections and services for women, legislation such as this is urgently needed to make sure that Californians are able to access the full range of reproductive care regardless of where they may live, Leyva said in a statement.

Follow this link:
Calif. Legislature Passes Bill Mandating All Public Colleges Offer Free Medical Abortions - The New American

Recommendation and review posted by Bethany Smith

The Polycystic ovary syndrome, or polycystic ovary syndrome, is one of the most common metabolic disorders of Mature women, worldwide, about five to eight percent affected. Prominent patients Victoria Beckham or Jools, wife of celebrity chef Jamie Oliver, for example.

polycystic ovary syndrome What is it?

Noticeable PCOS, among other factors, due to Obesity, cycle irregularities, infertility, and the growth of a beard. One of the most common symptoms of PCO syndrome is that Sufferers have difficulty to get pregnant, however, both Victoria as well as Jools the proud mommies of four children. This shows that Even if the PCO-syndrome is not curable, treatment is possible.

The polycystic ovary syndrome, women have elevated levels of male sex hormones like testosterone and suffer from a dysfunctional cycle to infertility. Additional symptoms may include acne, weight gain, loss of hair on the head and strong body hair, in addition, suffer from the disease, other diseases such as Diabetes, heart, Depression, or sleep apnea favors. A treatment is therefore absolutely necessary! Dr. Israel Ortega of the Spanish clinic IVI Fertility, said: Unfortunately in the medical world today still some confusion about what PCOS is caused. It is believed widely that it has to do with the genes, however, still needs to be scientifically proven.

How can you treat PCOS?

The patients who suffer from PCOS have a hormonal imbalance. This is also a factor that contributes to the disease. As with all diseases, the symptoms, as well as your vary in polycystic ovary syndrome severity.

Who presents the typical symptoms associated with PCOS in connection, in itself, should arrange first an appointment with his family doctor, to perform the necessary Tests, and other diseases can exclude. Sometimes you can perhaps even an ultrasound and or a blood test. After a diagnosis you will be referred possibly to a PSCOS specialists that can help you to be in the best possible way with the symptoms to be done.

So, for example, the pill can help with irregular cycles, while women should be transferred with the Baby in advance, to an appropriate fertility specialist.

diet for polycystic ovarian syndrome

a special diet can help, because studies have shown that a weight loss of five per cent, helped overweight women to alleviate their PCOS symptoms. It is recommended, above all, a sugar-reduced diet. The Basis of the diet are vegetables, and sugar-poor fruits. Aussrdem must. according to the 3 meals-principle, without Snacks in between feed, which activates the burning of fat and helps in calories to save, because who eats often eats usually more

high-Quality protein suppliers, such as lean meat, fish, eggs, low-fat dairy products are recommended, and white flour products should be avoided rather. The experts especially recommend the dish model-diet to combat polycystic ovary syndrome in a natural way. (CM)

in order To successfully and in the long term, lose weight, the calorie intake is of great importance. Not only eaten, but also the composition of meals plays an important role. In addition, the plate model is perfect information, and all menus, no matter whether you consume these in the Restaurant, at home, or in the case of an invitation to apply.

In Switzerland, about one in ten sex suffers Mature woman complaints for the period. Much has been written about the symptoms of Premenstrual syndrome (PMS), although it is not known, but there are certainly ways on how you can take action against the symptoms.

Here,

Of endometriosis read more, if there are uterine lining attaches outside the uterine cavity such as the peritoneum, ovaries, Uterus, vagina, bladder or bowel. The blood of the endometriosis foci can not flow out. Often inflammation is the result. Symptoms strong menstrual cramps, pain during Sex and bowel movements, cycle disorders. Endometriosis does not always cause pain, sometimes it is only discovered in the wish to have children. Doctors believe that occurs in about 50 percent of infertile women.

hormone therapy, pills, or a laparoscopy, at which the flock can be removed Help. The relapse rate is high. In the past, Doctors suggested a pregnancy as a therapy, it discourages today. A pregnancy does not necessarily improvement. Affected births have an increased risk for complications and failure.The removal of the uterus and ovaries is associated with risks. Only with the Menopause, the disease takes a the end.

See original here:
What polycystic ovary syndrome is and what it means for those Affected? View - The KXAN 36 News

Recommendation and review posted by Bethany Smith

This article was medically reviewed by Connie Jennings, M.D., a member of the Prevention Medical Review Board, on September 12, 2019.

Before we dive into essential oils, know this: The best way to ward off a cold is to wash your hands. A lot. Often. Then again. Most doctors agree that this is the number-one way to stay healthy while people around you are wheezing and sneezing and dripping mucus. But isnt it nice to know that there are other natural ways to ward off the ickiesand that they (bonus!) smell great? Essential oils to the rescue!

Essential oils have been used by generations of people, in a multitude of cultures, as a natural preventative and treatment for a host of ailments, and that includes the common cold. "As far back as the Paleolithic period60,000 years agohumans were using plants as herbal remedies," says Yufang Lin, MD, a board-certified physician who practices at Cleveland Clinic Wellness. "Unlike pharmaceuticals, one plant often has multiple properties. Lavender, for instance, has anti-inflammatory, anti-septic, anti-anxiety and anti-depressant properties."

Like many natural remedies, there hasnt been a huge amount of research done on essential oils, since studies are (unfortunately) often driven by the marketplacebut there have been a certain number of studies on some essential oils. When it comes to using them to ward off colds and coughs and easing the discomfort they cause, keep reading for more on what's known about specific oils.

There are a few easy methods for using essential oils to help with the sniffles.

Tea Tree Oil: According to one study, this oil has been found to have antiviral properties, meaning it could help squelch the nasties that lead to sinus infections and respiratory issues. "Tea tree essential oil has also been proven to have antimicrobial and antifungal properties," says Dr. Lin. "It's one of my favorites for cold season, along with eucalyptus and lavender."

Eucalyptus Oil: Beyond its forest-y scent, eucalyptus oil has been shown to have both antiviral and antimicrobial properties. "It also reduces inflammation, suppresses cough, reduces fever, loosens up chest congestion, and is an all-around support during cold season," says Dr. Lin. Dilute it in one of the neutral oils above and rub it onto chest and throat to ease a cough, or do a steam sauna (above). If youre feverish, you can also add it to a cool compress and it may just lessen your temp.

Peppermint Oil: That minty goodness is a natural decongestant and fever reducer, due to its menthol. A small study from 2013 found that it can help the bronchial musclesand could thus ease breathing if you have a cough. (Dont use this one while pregnant.)

Chamomile Oil: A 2010 study stated that breathing in chamomile essential oil in steam may help relieve cold symptoms.

Rosemary Oil: This herb isnt just a way to spark up your roast chicken! In its essential oil form, its been found to be good at breaking up mucus and reducing inflammation.

Frankincense Oil: Its anti-inflammatory power has been shown to be useful in treating coughs and bronchitis. The scent is woodsy and rich.

Oregano Oil: This essential oil has a compound that, according to one study, is a good antimicrobial germ-fighter.

Thyme Oil: With high levels of the same helpful compound as oregano, thyme oil may help protect against viruses and bacteria.

Cinnamon Oil: 2017 research showed that cinnamon oil could ward off germs that cause respiratory problems.

A critical component of staying healthy, warding off colds, and recovering? Getting enough sleep! Here are 4 essential oils known to promote relaxation and snoozing! (Chamomile oil, above, is another one that helps on this front.)

Lavender Oil: Lavender is one of the best-studied essential oils. Research has shown that it may help you go to sleep, and may even lower your levels of the stress hormone cortisol. Less stress, easier snoozing! "Lavender is well known for its ability to lift mood and reduce anxiety," says Dr. Lin. "Who wouldnt benefit from a mood lift when sick?"

Bergamot Oil: One study showed that sniffing bergamot aroma for just 15 minutes reduced cortisol levels.

Clary Sage Oil: With a grassy, herbal scent, this oil eases stress and makes you feel sleepy. Put a drop or two on a tissue, cup it in your hands, and breathe in deeply for a couple of minutes.

Sandalwood Oil: Another rich and woodsy scent; one study found that the oil has a sedative effect and can increase REM sleep (but for some people, it increases alertness! So maybe try it before a nap first).

"Because it takes a lot of plant materials to make the essential oilfor example, it takes 250 lbs. of lavender to produce one pound of essential oilthey are considered strong medicine," says Dr. Lin. "A little goes a long way, and toxicity is possible." Start by using a minimum amount and increase as tolerated. Dr. Lin adds, "Extra caution needs to be exercised around pregnant women, children, the elderly, those with multiple medical conditions, and pets."

Like what you just read? Youll love our magazine! Go here to subscribe. Dont miss a thing by downloading Apple News here and following Prevention. Oh, and were on Instagram too.

Read the original post:
These Are the Best Essential Oils for Colds and Coughs, According to a Physician - Prevention.com

Recommendation and review posted by Bethany Smith

In recent years, health officials have pushed aggressively to include more women in clinical trials of new drugs. Gone is the ban that once excluded women of childbearing age from participating in studies. Even scientists who work with animals are now encouraged to include mice and rats of both sexes.

But when it comes to breast cancer, it is men who get short shrift. They are often excluded from clinical trials of new treatments. When breast cancer drugs come to market, there is little data to indicate whether they are safe or effective in men. Some drugs are approved only for women.

The disease is extremely rare in men, who account for fewer than 1% of breast cancer cases. Nonetheless, the Food and Drug Administration is calling on researchers to include male patients in clinical trials of breast cancer treatments, even if the studies are unlikely to enroll more than a handful of men.

The guidance is a draft recommendation now open to public comment. Some breast cancer specialists called it a long overdue step.

Its so frustrating in clinic to see patients and say, Well, we dont really know the drugs have been tested in women. We think it should work in men, but theres no real evidence to back that up, said Dr. Sharon Giordano, a professor of breast medical oncology at M.D. Anderson Cancer Center in Houston who treats many male patients.

Even if only a few men participate in each trial, data on them could be pooled. Coupled with real-world experience using the medications, that data could shed light on treatment, she said.

The proposed guideline comes amid growing concerns that men with breast cancer whose disease tends to be diagnosed in more advanced stages are often not getting optimal care and may be missing out on lifesaving therapies.

One of the largest analyses of these patients, published in Annals of Oncology in 2017, reported what the authors called troublesome findings. The study, carried out by the International Male Breast Cancer Program, analyzed 1,500 men with breast cancer in Canada, the United States and seven European countries.

The vast majority of men with breast cancer have tumors that are fueled by estrogen. (Men produce the hormone, too.) In the study, virtually all men whose cancer had not spread had estrogen-receptor-positive tumors, which should be treated with therapy to reduce estrogen levels in the body or to block the hormone from attaching to breast cancer cells.

But only 77% of these patients received anti-estrogen therapy, the study found. That means that nearly 1 in 4 men who should have received a potentially lifesaving therapy did not get it, said Dr. Fatima Cardoso, the lead author of the study and director of the breast unit at Champalimaud Clinical Center in Lisbon. We dont know why, she said.

The most common treatment for men was surgery: a mastectomy to remove the breast, or a lumpectomy to remove the tumor. But the men had low rates of radiation treatment, which is standard care after a lumpectomy and often recommended after a mastectomy if, for example, the tumor is very large, said Dr. Marisa C. Weiss, founder of Breastcancer.org. The study called the low rates a major concern.

Poor care is all too common when patients suffer from rare diseases, and for men, breast cancer is a rare disease, Cardoso noted.

Many, many oncologists have never seen a case of breast cancer in a male patient, she said. For these patients, she added, its particularly important to find experienced doctors.

Men with breast cancer are often older. They may have very large tumors by the time they seek care, because they were not on the lookout for the disease.

Some men are not even aware they have breasts and not aware they can have breast cancer, Cardoso said. Even health professionals often dont think about it. General practitioners who see male patients dont pay attention to the breast.

She added: We need a lot of education to remind men they have breasts, too, and should check them. And if they find something, go to the oncologist fast.

Cardoso and other experts welcomed the proposed new guidelines, but said researchers should collaborate on large international trials focused on men with breast cancer. When the patient population is small, large trials are needed to make significant findings.

Some data is better than no data, but its not the ultimate solution, said Dr. Larry Norton, chairman of clinical oncology at Memorial Sloan Kettering Cancer Center in New York.

But pharmaceutical companies are not very interested in funding such trials. No one wants to invest in a disease that is only 1% of all breast cancers, Cardoso said.

As with women, one of the first warning signs of breast cancer in men can be a lump in the breast. Other possible early symptoms include nipple pain, discharge from the nipple, a sore on the nipple or areola, an inverted nipple, or swollen lymph glands under the arm.

The risk of breast cancer in men increases with age, and is higher in men who have high estrogen levels or genetic mutations or who have been exposed to radiation. Men with Klinefelter syndrome who carry an extra X chromosome are also at increased risk.

Family history is important: Doctors recommend all men with breast cancer be tested for mutations in the BRCA1 or BRCA2 genes, which are linked to both breast and ovarian cancer in women.

Men who have mutations in these genes are 80 times as likely to develop breast cancer as men without these mutations. A positive result alerts female relatives that they may need to be tested as well.

Read the rest here:
Who's missing from breast cancer trials? Men, says the FDA - NNY360

Recommendation and review posted by Bethany Smith

The testimony of his eight-year-old victim may put convicted rapist Nicolas Ninow away for life. Ninow was convicted of rape on Monday but not before many questioned the National Prosecuting Authoritys decision to risk re-traumatising his young victim by asking her to provide her testimony via cameras outside the courtroom. Joan van Dyk looks at how, in court, comfort for the tiniest victims of sexual abuse can come from the unlikeliest of places.

All rise, a voice declares as the magistrate enters the room. The Krugersdorp Magistrates Court is packed. A black and red robe drapes gracefully around the magistrates shoulders.In front of her, a shuffling ensues as people attempt to sit comfortably on the hard wooden benches.

Then, the room falls quiet in anticipation of the mornings proceedings.

But magistrate Kleio has become distracted.

She stops to sniff the air. Its suddenly filled with a delicious, meaty smell.

Suddenly, she spins around, gobbling up a treat from an outstretched hand behind her.

Sated and lips smacking, she shifts her focus back to the matter shes presiding over her short, black tail still wagging.

Kleio is one of a rotating pack of about 15 specially-trained therapy hounds that descend upon the Krugersdorp Magistrate Court west of Johannesburg every second Saturday.

Shes no ordinary magistrate.

This week, Kleio is flanked by, among others: Betty the stenographer, court orderly Peanut, and Flake the prosecutor. Each dog is dressed in a costume tailored to the role they take on in mock courtroom proceedings.

Travis, a shiny black labrador, has been cast in the role of the defense advocate. Hes sporting a patched, bedraggled toga to show that he represents the bad guy, Corrie Niemann explains.

Niemann is the vice president at Top Dogs, a volunteer organisation that specialises in training pups to take part in animal-assisted therapy. This kind of counselling pairs trained dogs such as Kleio with healthcare professionals, psychologists or teachers to help people recover frompsychological trauma or even heart disease, the US medical organisation Mayo Clinic explains on its website.

For about four years, Top Dogs has worked with Johannesburgs Teddy Bear Foundation. With several branches in Gauteng, the foundation supports children who have been sexually abused or neglected as well as their families through a range of counselling. The centres also provide the specialist medical care needed to collect physical evidence for those looking to open a case against the perpetrators.

Thats why Kleio and the gang are at the Krugersdorp Magistrates Court to play their part in the Teddy Bear Foundations court preparation programme for sexually abused children.

One in three South African children will have experienced some form of sexual abuse by the age of 17 enough children to fill Johannesburgs Soccer City stadium eight times.

More than 24 000 cases of child sexual abuse were registered by the South African Police Service last year a 4% increase in reported assaults since 2005, according to crime statistics released earlier this month.

These figures, however, only reflect cases that were reported to the police, and national and community-based studies suggest the real numbers are likely far higher, says Lucy Jamieson, a child rights researcher at UCTs Childrens Institute.

Research suggests that one in three South African children will have experienced some form of sexual abuse by the time they reach the age of 17 enough children to fill Johannesburgs Soccer City stadium eight times.

Thats according to the Optimus Study, which asked almost 10 000 South African teenagers between the ages of 15 and 17 if theyd ever experienced sexual violence, including rape and exposure to pornography. Because of the studys design, this figure also includes consensual sexual acts between 17 and 18-year-olds, which are legal in South Africa.

In South Africa, the age of consent is 16. But the countrys 2007 Sexual Offences Act provides for children between the ages of 12 and 16 to have sex with each other legally. Adults people 18 and older who have sex with children between the ages of 12 and 16 are guilty of statutory rape. The law does, however, allow for children aged 16 or 17 to legally have sex with people who are up to two years younger or older than themselves.

The research revealed children who had a supportive family environment, for instance, whose parents regularly knew who they were with and where they went, were far less likely to report having been sexually abused.

Similarly, the Optimus study echoed previous research in finding that children who lived with neither or just one biological parent had an increased risk of sexual abuse, with the risk being higher for young people living with neither parent than for those living with one biological parent.

Almost two-thirds of South Africa children live in single-parent households, a Statistics South Africas 2016 community survey revealed.

In 40% of cases, the Optimus Study found, South African children had been victims of abuse two or more times.

And, while about one in three children who were abused by an adult they know also reported having injuries, only about 30% of these children sought medical help.

Its a dry and icy August day at the Krugersdorp Magistrates Court. Inside courtroom F, about 30 children sit fidgeting on benches a sea of puffy jackets in blue and purple hues.

Theyre all due to testify in court as witnesses in sexual abuse cases. Most likely their own.

Even in cases that never make it to court, children may be required to give eyewitness reports during the course of the investigation or to determine their emotional and intellectual competency to testify. And for victims of abuse, the stress of this process can cause more trauma, explains the clinical director at the Teddy Bear Foundation Shaheda Omar.

Children who experienced sexual abuse were three times as likely to report symptoms of post-traumatic stress disorder such as anxiety and nightmares than other young people, the Optimus study found.One in five children who have been sexually abused by adults are also likely to have problems with their schoolwork.

The more times a child testified, research found, the worse they coped with the trauma later on. But children were worse off even a decade later if they had not testified at all and their abusers received light sentences.

But for children who go on to testify against their abusers, this emotional distress can be even more severe even years after the case had ended, found a 2005 study published in the journal Monographs of the Society for Research in Child Development.

The researchers followed about 200 sexually abused child witnesses in the United States for 12 years after they testified in court in the 80s. Rape victims who had testified in court reported worse mental health than children who didnt, even after researchers took into account the psychological issues that were present before their cases started.

The more times a child testified, the worse off they were later in life, and the less likely they were to be able to adjust to everyday life when their case ended especially if their testimony was the only evidence to support their case.Although, victims were worse off in adulthood if they did not testify and the perpetrator was given a light sentence. These children reported higher levels of anxiety about whether they were believed.

Children who were older when they testified and had a better understanding of what their involvement in the legal system meant, remained negative about their experience of the legal system as they grew older. Younger childrens attitude however dissipated somewhat.

Thats why these youngsters are getting special training in Krugersdorp.

Who wants to be our magistrate today? sings the Teddy Bear Foundation staff member who runs the programme.

A few tiny hands shoot up they know the drill.

By the time the children gather for a practice-run in court, theyve already been taught about the different court characters in smaller group sessions with the dressed-up dogs, Omar says.

Depending on their age, they may also have filled out worksheets that help them come to grips with each ones role in the court. Theyll get to know the dogs after the court run-through too, in sessions set up specially to walk, brush or feed them.

This way, Omar explains, the children are less anxious and they get to know whos who in the zoo.

A young girl gets up, confidently takes a black robe from the smiling Teddy Bear Foundation staffer, and ambles up to take her seat next to Kleio, whos enjoying a luxurious head scratch from her handler. The dogs are never let off their leash, Niemann says.

When all the actors have been cast and handed their scripts, a mock court case begins but the details wont overlap with any of the real cases in which the kids are involved.

Today, magistrate Kleio is trying to get behind the case of a certain missing television, which the court has heard, was apparently shiny. And purple.

Plopped down in the hallway close to Shaheda Omars Parktown office is a giant plush teddy bear larger probably than most of the children that pass it on the way to therapy.

Sitting in her office, Omar is surrounded by the foundations namesake. Teddy bears dot a bookcase behind her, snuggled between psychology books and awards for the centres work. Opposite her desk, a row of the stuffed animals sit on the floor, propped up against a yellow wall next to tiny chairs set up especially for the centres little patients.

Courtrooms are not built for children, she says, adjusting the giant red bow pinned to the front of her blouse with a sparkly brooch.

Even less so when those children are victims of abuse.

She explains: Children who have experienced trauma often generalise their experience onto everything. Theyll be afraid of everything and everyone.

But a fascinating phenomenon begins to take shape when the kids start to trust the dogs. They become less fearful. And, the little ones gradually begin to trust their court preparation counsellors and social workers.

Omar chalks this up to the calming effect of the four-legged therapists: The dogs help them heal, she says.

And, theres science to back her up.

In 2017, researchers randomly assigned children between the ages of 7 and 12 to rooms where they were asked to do public speaking for five minutes, and then complete a maths problem all in front of an audience of two unencouraging adults they hadnt met before. The children faced this scary event either alone, with a caregiver, or with their pet dog. The kids who had their animal companions reported feeling less stressed than those in both the other two scenarios.

In the same study, children who petted their furry friends for comfort also had lower levels of the stress hormone cortisol. The study, published in the journal Social Development in 2017, concluded that pet dogs could act as a kind of stress buffer for children.

Locally, researchpublished in the South African Journal of Psychology in 2013, found therapy dogs even helped to improve traumatised childrens self-esteem and social skills.

At least one small, experimental study suggests the furry companions may also help adults.

A 2018 study published in the journal Frontiers of Psychology found that women who interacted with therapy dogs directly after being shown a traumatic film clip reported lower levels of anxiety than those who were simply shown a video of a therapy dog or were left alone after seeing the footage.

But, animal-assisted therapy is a relatively new field, and aresearch review published in the Frontiers of Psychology in 2015 found that while this kind of intervention could be useful to treat trauma in conjunction with traditional methods such as counselling, more work is needed to determine whether it can be used as a stand-alone treatment.

In the meantime, the Teddy Bear Foundation has found that the more relaxed the children arewhen testifying in court, the better witnesses they become.

And that trend has been bad news for the bad guys. The organisations data shows their conviction rates have steadily improved since Top Dogs became involved in their court preparation programme.

But its not just the dogs, Omar argues. It takes a whole team of experts including lawyers, police officers, psychologists and parents to prepare a child to testify in court.

Its not about coaching the child what to say, she says, as the morning sun bounces around her brightly coloured office.

Its about teaching him or her to retell the events as they remember it unfolding. And that its okay if you dont remember, to just say so.

Back in the cold stuffy courtroom in Krugersdorp, magistrate Kleios human counterpart is inching ever-closer to her.

What weve seen is that the children slowly start testing the waters, getting closer, closer and even start touching the dogs, Omar says. Even those that initially cried or avoided the dogs and showed resistance, start engaging with the dogs.

By the time the fake session draws to a close, a glance around the courtroom reveals more and more tiny hands resting on furry backs.

Just before the court adjourns, a loud thump echoes around the courtroom.

Then, snorts and giggles. Flake, the shiny black dog dressed as a prosecutor, has tumbled off his chair. A stretch gone too far.

Its a tough life, that of a therapy dog, but before everyone can leave the stuffy courtroom to romp around outside, the teacher asks the class to recap questions about what theyve learnt.

And what is the role of the witness? the teacher asks.

From the front row, a tiny little girl, around 5 years old, puts up her hand and answers proudly: To tell the truth.

The Teddy Bear Foundation hopes to expand the court preparation programme, which currently only runs in two centres in Johannesburg and Krugersdorp. If everything goes according to plan, the first new satellite clinic will be in Soweto, Omar says.

Luckily, since the court preparation programme depends mostly on the work of volunteers, it doesnt cost much to run. The foundation estimates the programme costs about R1 000 to run per year.

As for the dogs, theyll work for the odd tummy rub. The trouble is finding enough pet owners willing to offer their pets to be trained for the job.

Well need 15 more volunteer handlers and dogs for each new site, Top Dogs Corrie Niemann explains.

Niemann dreams of a day when dogs will make their first appearance in South Africas courts.

In the United States, more than 200 dogs work in 40 states around the country, the non-profit Courthouse Dogs estimates.The dogs are also one of several options given to young people in Canada who need help getting through tough court cases.

But here at home, Omar adds, children are not always in the court session. In some cases, children testify, as Nicholas Ninows victim did, in camera or in a private room accompanied by a social worker. Niemann is adamant that even in this setting, a furry companion could make a world of difference.

For now, he and his team provide children with a knitted teddy bear, shaped to look like their favourite therapy dog to hold onto as they take the stand.

More:
The magistrate's tail: How these pets are helping child rape victims get justice - Bhekisisa

Recommendation and review posted by Bethany Smith

Stem cell-derived cells are ready-made human induced pluripotent stem cells (iPS) and iPS-derived cell lines that are extracted ethically and have been characterized as per highest industry standards. Stem cell-derived cells iPS cells are derived from the skin fibroblasts from variety of healthy human donors of varying age and gender. These stem cell-derived cells are then commercialized for use with the consent obtained from cell donors. These stem cell-derived cells are then developed using a complete culture system that is an easy-to-use system used for defined iPS-derived cell expansion. Majority of the key players in stem cell-derived cells market are focused on generating high-end quality cardiomyocytes as well as hepatocytes that enables end use facilities to easily obtain ready-made iPSC-derived cells. As the stem cell-derived cells market registers a robust growth due to rapid adoption in stem cellderived cells therapy products, there is a relative need for regulatory guidelines that need to be maintained to assist designing of scientifically comprehensive preclinical studies. The stem cell-derived cells obtained from human induced pluripotent stem cells (iPS) are initially dissociated into a single-cell suspension and later frozen in vials. The commercially available stem cell-derived cell kits contain a vial of stem cell-derived cells, a bottle of thawing base and culture base.

The increasing approval for new stem cell-derived cells by the FDA across the globe is projected to propel stem cell-derived cells market revenue growth over the forecast years. With low entry barriers, a rise in number of companies has been registered that specializes in offering high end quality human tissue for research purpose to obtain human induced pluripotent stem cells (iPS) derived cells. The increase in product commercialization activities for stem cell-derived cells by leading manufacturers such as Takara Bio Inc. With the increasing rise in development of stem cell based therapies, the number of stem cell-derived cells under development or due for FDA approval is anticipated to increase, thereby estimating to be the most prominent factor driving the growth of stem cell-derived cells market. However, high costs associated with the development of stem cell-derived cells using complete culture systems is restraining the revenue growth in stem cell-derived cells market.

Get Sample Copy of this report at https://www.persistencemarketresearch.com/samples/28780?source=atm

The global Stem cell-derived cells market is segmented on basis of product type, material type, application type, end user and geographic region:

Segmentation by Product Type Stem Cell-Derived Cell Kits Stem Cell-Derived Definitive Endoderm Cell Kits Stem Cell-Derived Beta Cell Kits Stem Cell-Derived Hepatocytes Kits Stem Cell-Derived Cardiomyocytes Kits Accessories

Segmentation by End User Hospitals Research and Academic Institutions Biotechnology and Pharmaceutical Companies Contract Research Organizations/ Contract Manufacturing Organizations

Request to View TOC at https://www.persistencemarketresearch.com/toc/28780?source=atm

The stem cell-derived cells market is categorized based on product type and end user. Based on product type, the stem cell-derived cells are classified into two major types stem cell-derived cell kits and accessories. Among these stem cell-derived cell kits, stem cell-derived hepatocytes kits are the most preferred stem cell-derived cells product type. On the basis of product type, stem cell-derived cardiomyocytes kits segment is projected to expand its growth at a significant CAGR over the forecast years on the account of more demand from the end use segments. However, the stem cell-derived definitive endoderm cell kits segment is projected to remain the second most lucrative revenue share segment in stem cell-derived cells market. Biotechnology and pharmaceutical companies followed by research and academic institutions is expected to register substantial revenue growth rate during the forecast period.

North America and Europe cumulatively are projected to remain most lucrative regions and register significant market revenue share in global stem cell-derived cells market due to the increased patient pool in the regions with increasing adoption for stem cell based therapies. The launch of new stem cell-derived cells kits and accessories on FDA approval for the U.S. market allows North America to capture significant revenue share in stem cell-derived cells market. Asian countries due to strong funding in research and development are entirely focused on production of stem cell-derived cells thereby aiding South Asian and East Asian countries to grow at a robust CAGR over the forecast period.

Some of the major key manufacturers involved in global stem cell-derived cells market are Takara Bio Inc., Viacyte, Inc. and others.

The report covers exhaustive analysis on: Stem cell-derived cells Market Segments Stem cell-derived cells Market Dynamics Historical Actual Market Size, 2014 2018 Stem cell-derived cells Market Size & Forecast 2019 to 2029 Stem cell-derived cells Market Current Trends/Issues/Challenges Competition & Companies involved Stem cell-derived cells Market Drivers and Restraints

Regional analysis includes North America Latin America Europe East Asia South Asia Oceania The Middle East & Africa

Report Highlights: Shifting Industry dynamics In-depth market segmentation Historical, current and projected industry size Recent industry trends Key Competition landscape Strategies of key players and product offerings Potential and niche segments/regions exhibiting promising growth A neutral perspective towards market performance

Purchase this report at https://www.persistencemarketresearch.com/checkout/28780?source=atm

See the original post here:
Stem Cell-Derived Cells Market to Record an Exponential CAGR by 2025 - Commerce Gazette

Recommendation and review posted by Bethany Smith

After quite a few teaser pictures on their social media platforms since August, BIOLIFE4D finally announced one of the biggest milestones for the company: they successfully 3D printed a tiny heart. But how small is the mini heart?Actually, it is about one quarter the size of a human heart.

The ability to 3D bioprint a mini-heart now gives the biotech firm a roadmap to achieve their ultimate goal: bioprinting a full-scale human heart viable for transplant. It is now a matter of optimizing processes and scaling up the technology for the pioneering company headquartered in Illinois.

Ravi Birla

With the structure of a full-sized heart and four internal chambers, the mini heart is replicating partial functional metrics compared to a full-sized heart as close as anyone has gotten to producing a fully functional heart through 3D bioprinting.The scientific milestone was accomplished at the companysresearch facility at JLABS in Houston, led by Ravi Birla, Chief Science Officer of BIOLIFE4D

3DPrint.com asked Birla about their achievement to understand how functional it is and how this project could lead to a fully beating organ in the future.

The functional performance of our mini-heart is not the same as a normal mammalian heart, though this is a future objective of the research, explained Birla. Our mini-heart is intended for use in drug cardiotoxicity screening, which means that the bar that it must achieve is less than the bar required for a viable transplanted organ. This is why the performance requirements for our mini-heart do not need to mimic a fully-functional animal heart at this point.

Bioprinting at BIOLIFE4D

As we move forward we will be optimizing our bioink as well as the bioprinting parameters which are needed for optimal functional performance, suggeted the expert, who alsopreviously served as the Associate Director of the Department of Stem Cell Engineering at the Texas Heart Institute in Houston.

So how did they do it? First on their list was developing a proprietary bioink using a very specific composition of different extracellular matrix compounds that closely replicate the properties of the mammalian heart. There is still no formal name to the bioinkas it was developed in-house and for now, it is currently intended for BIOLIFE4D use only.

Then, they got around creating a novel and unique bioprinting algorithm, consisting of printing parameters optimized for the whole heart. Coupling its proprietary bioink with patient-derived cardiomyocytes and its enabling bioprinting technology, BIOLIFE4D was able to bioprint a heart. Birla suggested that because of the strategic partnerships that they have developed, they have access to and utilize most of the commercially available printers which are on the market, but the mini-heart was essentially biofabricated in their labs using a CELLINK INKREDIBLE+.

We currently used a commercial source of human cells, through the expected use of the technology in using patient derived autologous cells, claimed Birla. Utilizing patient specific cells is really a cornerstone to our technology.

Currently those lucky enough to receive a donor heart transplant are really only trading one disease for another. The donor heart will save their life, but to prevent rejection the patient needs to take a large regiment of immunosuppressant therapy which causes many significant challenges for the patient. By bioengineering the heart out of the patients own cells we eliminate the need for that immunosuppressant therapy which could allow for a much better quality of life for the patient, he continued.

With this platform technology in place, BIOLIFE4D is now well-positioned to build upon it and work towards the development of a full-scale human heart. This latest milestone also positions the company as one of the top contenders at the forefront of whole heart bioengineering, a field that is rapidly advancing.

However, beyond the scientific advancements the mini-heart represents, this is also an opportunity to provide the pharmacological industry and drug discovery companies a new tool for cardiotoxicity testing of new drugs and compounds. Until now the model used for predicting the cardiotoxicity effects of a new drug or compound was essentially limited to the animal model.But BIOLIFE4D intends to ultimately provide the mini-hearts as a more reliable model of predicting cardiotoxicity, claiming that there is no better predictor of how a human heart will react than a human heart. This also represents an opportunity to reduce the number of animals used for testing purposes, something which is already banned in quite a few regions,including India, the European Union, New Zealand, Israel, and Norway.

We are already working closely with companies that provide cardiotoxicity testing services to the Pharma and drug discovery industries. All drugs, new compounds and anything else that currently undergoes cardiotoxicity testing requirements prior to entering the human market could be candidates for the mini-heart. After all, what would provide a better predictive model of how a human heart will respond than a human heart (albeit a scaled-down version)? revealed Birla.

The mini-heart has many of the features of a human heart even though BIOLIFE4D has not been able to recreate the full functionality of a human heart yet.

While we have bioengineered mini-hearts, and this in itself is a major accomplishment, a significant advancement in the field of whole heart engineering and moves us closer to bioprinting human hearts for transplantation, this accomplishment does not provide us with a specific time-line or a significant guidance on when the fully funcitional heart will be available.

According to Birla, the most difficult part to 3D print a human heart at this point is the valves, due to the complex tri-leaflet geometry. But as they begin to scale up, they can anticipate that the complex vasculature that is needed to keep an organ viable could prove to be a big challenge.

Birla is convinced that the algorithm used as a fundamental part of the mini-heart could change the way labs will bioprint organs in the future.Weused very specific and highly customized printing parameters to bioprint the mini-heart which we have customized for our use in our lab and for our specific purposes. Some of the process ultimately could be leveraged for the bioengineering of other organs, but our overall process to bioengineer a human heart is unique to a heart.

One of the huge advantages BIOLIFE4D enjoys is that they have been able to form strategic partnerships with various major research institutions and hospitals to provide them access to some of the most state-of-the-art facilities and equipment. Nevertheless, because of the highly confidential nature of their work, most of it is done in-house at the labs and by their own researchers.

The successful demonstration of a mini heart is the latest in a string of scientific milestones from BIOLIFE4D as it seeks to produce the worlds first 3D bioprinted human heart viable for transplant. Earlier in 2019, they successfully 3D bioprinted various individual heart components, including valves, ventricles, blood vessels, and in June of 2018 they 3D bioprintedhuman cardiac tissue(a cardiac patch).

The company states that their innovative 3D bioprinting process provides the ability to reprogram a patients own white blood cells to iPS cells, and then to differentiate those iPS cells into different types of cardiac cells needed to 3D bioprint individual cardia components and ultimately, a human heart viable for transplant.

This is crucial for a company that seeks to disrupt how heart disease and other cardiac impairments are treated, particularly by improving the transplant process so that in the future they can eliminate the need for donor organs. Heart disease is the number one cause of death of men and women in the United States each year. Heart diseases even claim more lives each year than all forms of cancer combined, yet countless individuals who need transplants are left waiting as there are not enough donors to meet demand and every 30 seconds, someone dies in the US of a heart disease-related event.

While we have come a long way, and we are moving forward at a fast pace, we just dont know how long it will take to achieve a full-scale heart. We have to keep in mind that mother nature had millions of years to perfect this process inside our bodies, while we just arent sure exactly how long it is going to take us to perfect the process outside of the body, concluded Birla.

At BIOLIFE4D, they know there are still challenges on the way to the full-size human heart viable for transplantation, however, this achievement signals that they are on the right path. They highlighted that their success, as well as the significant advancements they have been able to achieve already,are a result of an incredible team effort,a multi-disciplinary group of researchers working on the project, from bioengineers to life scientists.Their team consists of people with specific skill sets and areas of expertise, all working hard to bring this incredible life-saving technology to the market in the shortest time possible.

More:
Interview: BIOLIFE4D is The First US Company to Bioprint a Mini-Heart (for Cardiotoxicity Testing) - 3DPrint.com

Recommendation and review posted by Bethany Smith

Kari Branham, M.S., a genetic counselor at Kellogg, worked with Zions family to help them understand the genetic basis for Zions condition.

SEE ALSO: Retinitis Pigmentosa in Children: 5 Facts Families Should Know

We have seen such amazing progress with these conditions over the last 15-20 years,says Branham. We used to tell patients and their families that we would have to wait and see what happens, but now we can actually do something to help.

By going through the gene therapy process, Branham says the team is hopeful that this has changed Zions prognosis.

The treatment is designed to stop or slow the death of specialized cells in the retina, called photoreceptors, that send visual information to the brain.

Patients who have Leber congenital amaurosis have night blindness, says Besirli. One of the first treatment effects after receiving Luxturna is that (patients) are telling us that they function much better in dark.

LISTEN UP: Add the new Michigan Medicine News Break to your Alexa-enabled device, or subscribe to our daily updates on iTunes, Google Play and Stitcher.

They can play outside much longer, they can navigate around the house and dont need nightlights anymore and can participate in indoor sports. Thats been a huge change in their lives.

Seven months after treatment, Zion, now age 7, and his family are back to their normal routine in Montrose, Mich., and monitor his progress during follow-up appointments at Kellogg.

Zion says hes looking forward to playing football and, with improved vision -- playing outside at night with his brothers.

We hope that with Zion we have changed the trajectory for him to the point that in his 20s he wont have significant vision loss we see with him now, says Branham.

Read the rest here:
7-Year-Old Receives New FDA-Approved Retina Gene Therapy - University of Michigan Health System News

Recommendation and review posted by Bethany Smith

Sept. 19, 2019 06:38 UTC

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- The SanBio Group (SanBio Co., Ltd. and SanBio, Inc.)(TOKYO:4592), a scientific leader in regenerative medicine for neurological disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) Designation for SB623 cell therapy for the treatment of chronic neurological motor deficits secondary to traumatic brain injury (TBI). The designation is based on clinical results of SB623 including the Phase 2 Study of Modified Stem Cells in Traumatic Brain Injury (STEMTRA) trial.

Created under the 21st Century Cures Act, the RMAT designation is reserved for a regenerative medicine therapy intended to treat, modify, reverse, or cure a serious condition, and clinical evidence indicates that the therapy has the potential to address unmet medical needs for such disease or condition. Similar to the Breakthrough Therapy designation, the RMAT designation offers sponsors of cell and gene therapies eligibility for expedited development and regulatory review of their product candidate, including earlier and more frequent consultation with the FDA, and the potential for Priority Review and Accelerated Approval.

The RMAT designation for SB623 is an important regulatory milestone for SanBio as we investigate it as a treatment option for patients with chronic neurological motor deficits resulting from a traumatic brain injury, said Bijan Nejadnik, M.D., Chief Medical Officer and Head of Research. TBIs are one of the most common health conditions worldwide that often cause long-term complications or death. We look forward to working with the FDA on a potentially accelerated clinical development program to address this serious unmet medical need.

The RMAT designation augments the Sakigake Designation for innovative medical products from the Ministry of Health, Labour, and Welfare of Japan.

About SB623 SB623 is a proprietary, cell-based investigational product made from modified and cultured adult bone marrow-derived mesenchymal stem cells that undergo temporary genetic modification. Implantation of SB623 cells into injured nerve tissue in the brain is expected to trigger the brains natural regenerative ability to recover lost motor functions.

SanBio expects to initiate a Phase 3 trial for SB623 for the treatment of chronic neurological motor deficits secondary to TBI by the end of the fiscal year ending January 31, 2021. SB623 is also currently in a Phase 2b clinical trial for treatment of chronic motor deficit resulting from ischemic stroke.

About the Study of Modified Stem Cells in Traumatic Brain Injury (STEMTRA) Trial STEMTRA was a 12-month, Phase 2, randomized, double-blind, surgical sham-controlled, global trial evaluating the efficacy and safety of SB623 compared to sham surgery in patients with stable chronic neurological motor deficits secondary to TBI. In this study, SB623 cells were implanted directly around the site of brain injury.

To be eligible for this trial, patients (ages 18-75) must have been at least 12 months post-TBI and had a Glasgow Outcome Scale extended (GOS-E) score of 3-6 (e.g., moderate or severe disability). Patients must also have been able to undergo all planned neurological assessments and had no seizures in the prior three months. The primary endpoint was mean change from baseline in Fugl-Meyer Motor Scale (FMMS) score which measures changes in motor impairment at six months. The STEMTRA trial enrolled 61 patients from 13 surgical and 18 assessment sites in the U.S., Japan and Ukraine.

In this study, SB623 met its primary endpoint, with patients treated with SB623 achieving an average 8.3 point improvement from baseline in the FMMS, versus 2.3 in the control group, at 24 weeks (p=0.040). Of patients treated with SB623, 18 (39.1%) reached a 10 or more point improvement of FMMS compared to one control patient (6.7%; p=0.039). No new safety signals were identified. The most commonly reported adverse event were headaches.

About SanBio Group (SanBio Co., Ltd. and SanBio, Inc.) SanBio Group is a regenerative medicine company with cell-based products focused on neurological disorders in various stages of research, development and clinical trials. The Companys lead asset, SB623, is currently being investigated for the treatment of several conditions including chronic neurological motor deficit resulting from ischemic stroke and traumatic brain injury. SanBio has received a Japanese marketing license for regenerative medicine products from the Tokyo Metropolitan Government, and plans to begin marketing regenerative medicine products in Japan by the end of the fiscal year ending January 31, 2021. The Company is headquartered in Tokyo, Japan and Mountain View, California, and additional information about SanBio Group is available at https://sanbio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190918006094/en/

Read more here:
SanBio Granted Regenerative Medicine Advanced Therapy Designation from the US FDA for SB623 for the Treatment of Chronic Neurological Motor Deficits...

Recommendation and review posted by Bethany Smith

Study Touts Preventative Nerve Damage Imaging for 600,000 Annual Surgical Patients; Gene Therapy Research Looks to Increase 5-Year LSD Survival Rate

CULVER CITY, Calif., Sept. 13, 2019 /PRNewswire-PRWeb/ -- Two studies presented at the annual Congress of the World Molecular imaging Society (WMIS) focused on non-invasive real-time tracking of gene therapy and advances to decrease nerve damage using Fluorescence image-guided surgery.

With mean survival rate of five years (and most cases fatal) lysomal storage diseases (LSD) are among the most dismal of prognosis in all of medicine. In the study Real-Time Tracking of Gene Therapy by Bioactivated MR Probes, Thomas Meade, Ph.D., Professor, Northwestern University, stated that LSDs represent a large number of monogenetic diseases and, while rare, the prevalence is to hemophilia. The transformative results documented in an adeno-associated virus (AAV) gene therapy clinical trial in infants, affected by spinal muscular atrophy, demonstrated unequivocally the potential of in vivo gene transfer to treat monogenic neurological disorders. To date there is a lack of non-invasive ways to determine biodistribution or activity levels of these AAV therapies in patients.

"We pioneered the development of bioresponsive (bio-activated) MR contrast agents and since then the library of this class of probes has expanded from enzyme activated agents to include pH sensitive and redox activated," said Dr. Meade. "In our research, we want to determine if a new class of MR contrast agents could track the delivery of a gene by a noninvasive technique (MR imaging). The need for non-invasive, disease specific biomarkers that reflect treatment efficacy is paramount and not limited to gene therapy, but also applies to anything that augments the targeted enzyme activity."

According to Dr. Meade, his team is developing a new class of bioresponsive MR probes to track enzymatic activity in any organ, peripheral nervous system (PNS), or central nervous system (CNS) over time. As a result, gene therapy can be noninvasively monitored at both where and when the gene of interest is activated.

"The number of academic and biotech led programs has risen exponentially in the last few years," Dr. Meade concluded. "It is indeed an exciting and hopeful new era for the gene therapy field, but effective clinical trials with shortened paths to approval will require robust biomarkers to track therapeutic effect. It is our goal to support this important effort."

In the Nerve-Sparing Agents for IGS (Image Guided Surgery) presentation, Connor Barth, Ph.D., Senior Research Associate, Oregon Health & Science University, speaks about the widespread issue of resulting nerve damage from surgery.

"Nerve damage plagues surgical outcomes, significantly affecting post-surgical quality of life," said Dr. Barth. "Some 600,000 patients are affected by nerve damage during surgery annually in the United States. For some procedures, such as the radical prostatectomy, in which the prostate is removed as a prostate cancer cure, the rate of nerve damage can be as high as 60 percent."

During surgery, intraoperative nerve detection is completed using anatomical knowledge and conventional white light visualization when possible. However, neuroanatomy is variable between patients, especially in injured and diseased states that would be present during surgery, and nerves are typically protected deep within the tissue so that white light visualization is largely impossible. Fluorescence image-guided surgery offers a potential means for enhanced intraoperative nerve identification and preservation. To date, a variety of nerve-specific fluorophores have been tested in preclinical models; however, a clinically approved nerve-specific contrast agent does not yet exist.

"We have developed nerve-specific fluorophores that provide direct and buried nerve visualization during surgery with near-infrared fluorescence," Dr. Barth stated.

"The purpose of this study was to generate clinically relevant formulations and quantify the toxicity and pharmacology of our first-in-class, near-infrared nerve specific fluorophores. This work takes our technology one step closer to clinical translation for use during fluorescence-guided surgery."

Story continues

Dr. Barth believes this work will ultimately have a broad impact on surgical outcomes, significantly improving the rates of nerve damage during surgery and thus higher post-surgical quality of life for patients. This technology could also serve to make procedures available to surgeons where potential nerve damage has been prohibitive, broadening the clinical impact by enabling curative surgical treatments.

ABOUT WORLD MOLECULAR IMAGING SOCIETY

The WMIS is dedicated to developing and promoting translational research through multimodality molecular imaging. The education and abstract-driven WMIC is the annual meeting of the WMIS and provides a unique setting for scientists and clinicians with very diverse backgrounds to interact, present, and follow cutting-edge advances in the rapidly expanding field of molecular imaging that impacts nearly every biomedical discipline. Industry exhibits at the congress included corporations who have created the latest advances in preclinical and clinical imaging approaches and equipment, providing a complete molecular imaging educational technology showcase. For more information: http://www.wmis.org

# # #

The rest is here:
Nerve Damage Imaging and Single-Cell Tracking Gene Therapy are Highlights at World Molecular Imaging Society Annual Congress - Yahoo Finance

Recommendation and review posted by Bethany Smith

Researchers from the LSU School of medicine have recently found that metformin, a common diabetes treatment, may be effective in combatting cancer. The team found that the Type 2 diabetes drug could provide unique benefits to those with cancers that lack the Nischarin protein, often seen in breast cancer. This work was led by Suresh Alahari, PhD, Professor of Biochemistry and Genetics at LSU Health New Orleans School of Medicine and was published online in the International Journal of Cancer on September 16.

Nischarin, a protein molecule involved in tumor suppression and other biological processes, was discovered by Alahari. His research into this protein has been used largely in breast cancer, being that Nischarin expression is frequently reduced in this form of cancer. In this latest study, however, Alahari and colleagues showed that interfering with Nischarin expression can delay the development of the mammary gland, increase tumor growth and metastasis, and reduce the activation of AMPK.

The AMPK enzyme plays a pivotal role in metabolism and is thought to be therapeutic for metabolic diseases and potentially cancer. The full mechanism by which metformin acts is still unknown, but researchers have identified that the drug works in part by activating AMPK.

The clinical documentation that diabetic patients on a metformin regimen display reduced risks of developing cancer poses the tantalizing possibility that this approach to treating cancer might prove to be an effective and unrealized therapeutic opportunity, explained Alahari.

In their work, Alahari and colleagues showed that metformin successfully activates AMPK and inhibits tumor growth in malignancies that lack Nischarin. These findings indicate that metformin could serve as a powerful therapeutic agent in treating these unique tumors.

We found that Nischarin-deleted tumor cells had lower AMPK activity than Nischarin-positive cells, said Alahari. He continued to explain that metformin treatment activated AMPK more efficiently in Nischarin-deleted mice, and metformin suppressed tumor growth of Nischarin-deleted mice. Collectively, our data suggest that Nischarin disruption promotes breast tumor development, AMPK signaling is important for Nischarin-mediated suppression of breast tumors, and activation of AMPK by metformin suppresses breast tumor growth in Nischarin-lacking mice.

Breast cancer often displays reduced expression of Nischarin, particularly in triple-negative breast cancers. Impacting 2.1 million women every year, breast cancer is the most commonly occurring cancer among women as per the World Health Organization. Being that this disease accounts for roughly 15% of all cancer deaths among women, finding effective treatments is of paramount importance. With these new findings regarding metformins ability to combat Nischarin-lacking cancer, Alaharin and colleagues have made a breakthrough in the treatment of breast cancer and other tumors.

The discovery that the effectiveness of certain drugs, such as metformin, are influenced by the level of Nischarin expression could help identify specific patients in whom it is most likely to prove beneficial, added Alahari. In this way, Nischarin expression could serve as a biomarker to help inform decisions in management by identifying a subset of patients most likely to benefit from AMPK activator therapies.

In this work, Alahari was joined by LSU researchers Shengli Dong, Rajamani Rathinam, Steven Eastlack, Mazvita Maziveyi, and Bernardo Ruiz-Calderon. Their research was backed by funding from both LSU Health New Orleans and the Fred G. Brazda Foundation.

More here:
Using Diabetes Medication to Treat Breast Cancer - DocWire News

Recommendation and review posted by Bethany Smith

SAN FRANCISCO, Sept. 19, 2019 (GLOBE NEWSWIRE) -- Cellworks Group, Inc., a leader in Precision Medicine and a global pioneer of Therapy Response Index (TRI) technology, today announced that Blood Advances, an American Society of Hematology Journal, published results from the iCare 1 Clinical Study, which used Cellworks Genomic Biosimulation platform to predict therapy responses for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) patients. The prospective study was designed to assess the biological and clinical predictive values of the genomics-informed computational biology modeling (CBM) of patients with AMLand MDS by comparing biosimulated predictions of treatment responses with actual clinical responses.

The iCare 1 prospective study demonstrated 90% accuracy for predicting response to Standard of Care (SOC) treatments in Acute Myeloid Leukemia (AML)and Myelodysplastic Syndromes (MDS) patients. Cellworks unique genomics-informed CBM technology was used in this study to understand the mechanisms of relapse after chemotherapy treatment and to propose new re-induction treatment options for the relapsed patients in this study.

Next-generation sequencing (NGS) has revealed a high number of genomic abnormalities in each MDS and AML patient, as well as a high level of diversity among patients, said Dr. Christopher R. Cogle, MD., Professor at the University of Florida College of Medicine. As clinicians, our greatest challenge is to interpret this high number of genomic abnormalities and genomic diversity into a personalized treatment for our patients. The limitations of time in clinic and the complexity of each patients disease demand that we use technologies like Cellworks biosimulation for the best care of our patients.

Cellworks computational biology modeling (CBM) and digital drug biosimulation platform relies on somatic gene mutations and gene copy number variations (CNVs) found in individual MDS or AML patients. Genomic abnormalities are converted by the computational system into patient-specific protein networks to generate a virtual disease model. The patient-specific disease models are then interrogated using a drug library via biosimulations based on mathematical modeling to predict phenotype response including inhibition of disease cell proliferation and survival.

For this prospective study, 120 patients with AML or MDS were recruited to assess the predictive accuracy of Cellworks CBM by comparing computer predictions of treatment response to actual clinical outcomes. Of the 120 patients, 96 patients had full genomic testing profiles and 50 were eligible for evaluation based on length of follow-up. For the 50 patients, 61 treatments were administered. Cellworks CBM maps of the 32% relapsed samples from iCare 1 patients accurately matched the patient's nonresponse of treatment at relapse and identified mechanisms for chemo-resistance in these patients.

NGS alone does not provide enough information to deliver personalized oncology, said Yatin Mundkur, CEO of Cellworks. By using NGS data as input to biosimulation modeling, we can accurately predict individual patient therapy responses and prevent patients from undergoing unnecessary therapy regimens, thereby avoiding toxic side effects. By improving the accuracy of the treatment selection, we can also reduce health care costs and help increase physician productivity.

Cellworks is transforming personalized cancer therapy through genomic biosimulation software models that represent biomolecular and physiological pathways using the genomic data of each patient. Cellworks personalized medicine predictions help transform lives through the early adoption of successful therapies, while saving time and cost across the healthcare ecosystem. Cellworks also benefits the biopharma industry through virtual clinical trials, improved target identification, lead validation and the ability to repurpose and rescue drugs.

About Cellworks Group, Inc.Cellworks Group, Inc. is a world leader in Precision Medicine in the key therapeutic areas of Oncology and Immunology. The Cellworks unique biosimulation platform is a unified representation of biological knowledge, curated from heterogeneous datasets, applied to finding cures. Backed by Sequoia Capital and Artiman Ventures, Cellworks has the worlds strongest transdisciplinary team of molecular biologists, cellular pathway modelers and machine learning software technologists working toward a common goal attacking serious diseases to improve the lives of patients. The company is based in San Francisco, California with a research and development facility in Bangalore, India. For more information, visit http://www.cellworks.life and follow us on Twitter @CellworksLife.

All trademarks and registered trademarks in this document are the properties of their respective owners.

Media Contacts:Barbara Reichert, Reichert Communications, LLCbarbara@reichertcom.com650-548-1002

Michele Macpherson, Chief Business OfficerCellworks Group, Inc.michele@cellworksgroup.com

Read the original:
Blood Advances Publishes Cellworks Prospective Genomic Biosimulation Study that Predicts Cancer Therapy Response with 90% Accuracy - GlobeNewswire

Recommendation and review posted by Bethany Smith

An early-stage update on Adverum Biotechnologies intravitreal gene therapy has triggered investor concern, after patients with wet age-related macular degeneration (AMD) saw their vision deteriorate, despite signs that the treatment is improving retinal anatomy.

Adverum, on Wednesday, unveiled 24-week data from the OPTIC trial of its experimental therapy, ADVM-022, in six patients who have been administered with one dose of the therapy. On average, patients in the trial had severe disease with an average of 6.2 anti-VEGF injections in the eight months prior to screening and an average annualized injection frequency of 9.3 injections.

Over the six month period, patients did not require any anti-VEGF rescue injections and five of six patients saw a complete response with a total resolution of fluid following the Adverum injection. There were no serious adverse events, and the majority of side-effects were mild.

However, patients lost visual acuity by two letters on average, with a 90% confidence interval of -9.1 letters to +5.1 letters.

The range of individual patient data were not presented, though the wide confidence interval suggests that some patients may have experienced a loss of more than 10 letters during the course of the trial lack of rescue injections is difficult to square with declining vision. SVB Leerinks Mani Foroohar wrote in a note.

However, the study investigator insisted no loss in vision was due to wet AMD pathology and observed loss of visual acuity is due to normal variabilityin a small set of patients an assertion that, if proved out with additional follow-up, would very substantially improve the implied quality of this dataset.

Shares of the company which spectacularly failed years ago when it was christened Avalanche Biotechnologies $ADVM were down about 6.8% to $5.56 in Friday premarket trading. The stock sank on Thursday, evaporating millions from its market value.

This data suggest ADVM-022 is potentially active in delivering an expressible gene cassette in wet AMD, but mixed signals in this small dataset should lift some of the competitive overhang on RGNX shares, Foroohar added. RegenexBio experimental gene therapy for wet AMD, RGX-314, is currently in a Phase I/II trial.

Wet AMD, which is characterized by blurred vision or a blind spot in an individuals visual field, is typically caused by abnormal growth of blood vessels that leak fluid or blood into the macula. Macular degeneration is the leading cause of severe, irreversible vision loss in the elderly. Anti-VEGF injections such as Regenerons $REGN flagship Eylea, as well as Roches $RHBBY Lucentis and Avastin, are commonly used to treat wet AMD.

In April, the FDA imposed a clinical hold on an application to test ADVM-022 in humans, asking for additional data on Adverums chemistry, manufacturing and control process. In May, the hold was lifted. Late last year, the biotech abandoned its then lead experimental drug, ADVM-043, for the treatment of A1AT deficiency.

Go here to see the original:
Early snapshot of Adverum's eye gene therapy sparks concern about vision loss - Endpoints News

Recommendation and review posted by Bethany Smith

Find a random person on the street and ask them what a cancer drug should do. What are the odds they dont say it should help patients live healthier and longer?

A confluence of forces have pushed clinical trials away from that seemingly central question, with developers and patient groups betting on the promise that aiming at more subtle measures can help bring needed therapies to market faster. But a new study from the British Medical Journal suggests the conventional wisdom may be right and that trend, among others, have led cancer drugs to hit the market based off studies that have a high risk of bias.

Researchers led by London School of Economics Professor Huseyin Naci tracked cancer drug approvals by the European Medical Association over three years from 2014 to 2016. Putting aside 13 trials not based on a randomized control model which have their own set of issues but can be useful for rare diseases and two trials without published data, they evaluated 39 trials that formed the basis of drug approvals in that period according to a standard criteria of bias and found: 19 (49%) were at high risk of bias and the ones that didnt look at improving survival were more likely to be at risk. Only 10 trials primarily looked at improving survival.

Among them, 20% of trials that looked at overall survival had a high risk of bias, compared to 55% of the rest.

Other factors besides endpoint were at play in studies at risk for bias, including missing data and red flags in how data were measured, such as the trial lacking a blinded assessment.

But in their discussion of the results, the authors focused in part on the paucity of trials that looked head-on at whether a drug will help patients survive, warning that trials that look at other surrogate endpoints speed up development but might mislead patients and bring drugs that dont work. Evaluating the study in a BMJ opinion column, Barbara Mintzes and Agnes Vitry took similar aim.

Uncertainty and exaggeration of the evidence that supports approval of cancer drugs causes direct harm if patients risk severe or fatal adverse effects without likely benefit, they wrote. Or forgo more effective and safer treatments.

The push toward these surrogate measures has come from both developers, eager to get their treatments to market, and patient groups hoping to secure access to new remedies as fast as possible. Targeting overall survival on average takes about an extra year, time many cancer patients dont have.

A federal law, the 21st Century Cures Act, that went into effect in 2017 codified that push. Yet data on trials that avoid the central question of elongating and improving quality of life have been mixed.

A 2018 JAMA Internal Medicine review of 52 articles covering 38 trials on a total of 14,000 patients with 12 different cancers from 2000 through 2016 found no significant association between progression-free survival and health-related quality of life.

The study also comes as one of many critically evaluating existing scientific literature in the wake of the replication crisis that broke out most publicly in psychology and has rippled across the sciences. In 2012 Amgens head of research, Glenn Begley,published a paper inNaturerevealing a 10-year company effort to reproduce 53 landmark studies in oncology. They got positive results in 6.

Follow this link:
Cancer trials aimed at 'surrogate' targets miss bigger mark study - Endpoints News

Recommendation and review posted by Bethany Smith

It was the cellular equivalent of opening your car door and finding an active, roaring engine in the driver seat.

Scientists learned strands of DNA could occasionallyappear outside of its traditional home in the nucleus in the 1970s, when they appeared as little, innocuous circles on microscopes; inexplicable but apparently innate. But not until UC San Diegos Paul Mischel published his first study in Sciencein 2014 did researchers realize these circles were not only active but potentially overactive and driving some cancer tumors superhuman growth.

That insight and the ensuing five years of research will now get $46 million cash and company infrastructure to ramp into targeted therapies as Boundless Bio emerges from stealth mode with backing from ARCH Venture Partners and City Hill.Questions abound, from what precisely a drug would look like to what even gives rise to these wild DNA, but CEO Zachary Hornby isnt biting his tongue on the potential.

Were thinking about this as a fourth revolution in cancer therapies, Hornby, who was most recently COO of Ignyta, told Endpoints News. The first three revolutions, by Hornbys count, are chemotherapy in the 1940s, the first targeted therapies at the end of the 20th century, and the recent rise of immunotherapy.

The road to such a revolution would be long, but the embattled oncology field may be in need of new direction. A study released in April found 97% of cancer drugs tested in clinical trials failed to make it to market, and this month researchers found systemic targeting problems plagued two decades of cancer research.

The connection between this loose DNA, officially called extrachromosomal DNA or ecDNA, and cancer centers around a baffling and deadly fact about some tumors: While normal cells in a higher-order species like humans dont evolve within a generation, some cancer cells can evolve rapidly, ensuring their survival against attempted treatments. Why? How? Mischels mapping of cancer genome points to ecDNA.

Freed from a cells chromosomes, the DNA can replicate rapidly. That doesnt hurt if they code for nothing or something benign, but if they code for something that gives the cell an advantage, such as EGFR (a growth factor), the cells will grow rapidly as in any classical natural selection model. This, Hornby said, appears in over 25% of cancers, including notoriously hard to treat MET cancers.

EGFR inhibitors already exist to combat cancer cells that have already evolved (or been amplified), but Boundless Bio plans to use Mischels insights to destroy ecDNA in its early stages. Rather than attacking tumors after the cells have already amplified, the company would jam the process that gives rise to the evolution in the first place.

It opens a whole new avenue of cancer targets, including allowing us to pursue patient populations that to this point have been undruggable, Hornby said, pointing to MET and Myc. Thats just a really different approach than your typical targeted therapies.

But how they would do this is still cloudy.

Hornby said the most promising method was jamming the enzymatic machinery the molecular tools and parts that allow DNA to replicate and code proteins as their research has shown the machinery is slightly different in ecDNA than typical DNA. Another method theyre exploring is to inhibit the metabolic pathways ecDNA can use to fulfill the demands caused by its high replication rate; in other words, growing DNA that are hungry and depriving them of food could neutralize them.

Among the most notable things about Boundless potential therapies is that they may be approved for tumor type, rather than cancer type, i.e. like the new drug from Hornbys old company Ignyta, it could treat a wide range of cancers if the patient showed ecDNA was amplifying in the tumor.

The company will also invest in research to discover the underlying mechanism giving rise to ecDNA.

Originally posted here:
'A fourth revolution in cancer therapies': ARCH-backed Boundless Bio flashes big check, makes bigger promises in debut - Endpoints News

Recommendation and review posted by Bethany Smith

A comprehensive analysis of the Gene Therapy Market including market sizing, market share by competitor, market share by distribution channel, drivers, restraints, product pricing trends, industry quotations, company profiles and market forecasts to 2024 for global market. Gene Therapy market report provides investors, analysts, researchers, business executives and others with analyses and forecasts for the Gene Therapy market, including Gene Therapy production, revenues, competitors marketing strategy and global product selling prices up to 2022.

AccessGlobal Gene Therapy Market Research ReportDetails at: athttps://www.pioneerreports.com/report/197079

About Gene Therapy Industry

The overviews, SWOT analysis and strategies of each vendor in the Gene Therapy market provide understanding about the market forces and how those can be exploited to create future opportunities.

Key Players in this Gene Therapy market are:

Request for Sample Copy of this Gene Therapy Market Report athttps://www.pioneerreports.com/request-sample/197079

Important application areas of Gene Therapy are also assessed on the basis of their performance. Market predictions along with the statistical nuances presented in the report render an insightful view of the Gene Therapy market. The market study on Global Gene Therapy Market 2018 report studies present as well as future aspects of the Gene Therapy Market primarily based upon factors on which the companies participate in the market growth, key trends and segmentation analysis.

Application of Gene Therapy Market are:

Product Segment Analysis of the Gene Therapy Market is:

Look into Table of Content of Gene Therapy Market Report at https://www.pioneerreports.com/TOC/197079

This research report consists of the worlds crucial region market share, size (volume), trends including the product profit, price, Value, production, capacity, capability utilization, supply, and demand and industry growth rate.

Geographically this report covers all the major manufacturers from India, China, USA, UK, and Japan. The present, past and forecast overview of Gene Therapy market is represented in this report.

Inquire for further detailed information of Gene Therapy Market Report at:https://www.pioneerreports.com/pre-order/197079

Research objectives of Gene Therapy Market:This report provides pin-point analysis for changing competitive dynamics

It provides a forward looking perspective on different factors driving or restraining market growth

It provides a six-year forecast assessed on the basis of how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

Key Benefits of having Gene Therapy Market Report This report will help to develop Business Strategies by understanding the trends shaping and driving Gene Therapy market Organize sales and marketing efforts by identifying the best opportunities for Gene Therapy market To understand the future market competition in the Gene Therapy market.

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Report Price: USD 3900

No of Pages in Gene Therapy Market: 145

Analysis & Forecast Time Period: 2015-2024

Purchase Reportathttps://www.pioneerreports.com/checkout/197079

See the article here:
Gene Therapy Market Analysis by Major Companies, Segmentation, Market Dynamics & Trends - Real Viewpoint

Recommendation and review posted by Bethany Smith

Zacks Investment Research upgraded shares of Tocagen (NASDAQ:TOCA) from a hold rating to a buy rating in a research note published on Wednesday morning, Zacks.com reports. Zacks Investment Research currently has $1.00 price objective on the stock.

According to Zacks, Tocagen, Inc. is a clinical-stage, cancer-selective gene therapy company which focuses on retroviral gene therapy platforms. The companys lead product candidate consists of Toca 511 & Toca FC, initially for the treatment of recurrent high grade glioma, a disease with a significant unmet medical need. Tocagen, Inc. is based in San Diego, United States.

TOCA has been the subject of a number of other reports. ValuEngine upgraded Tocagen from a hold rating to a buy rating in a research report on Thursday, August 1st. Leerink Swann set a $5.00 price target on Tocagen and gave the stock a hold rating in a research report on Wednesday, May 22nd. Cantor Fitzgerald downgraded Tocagen from an overweight rating to a neutral rating in a research report on Thursday, September 12th. Robert W. Baird downgraded Tocagen from an outperform rating to a neutral rating in a research report on Thursday, September 12th. Finally, LADENBURG THALM/SH SH downgraded Tocagen from a buy rating to a neutral rating in a research report on Thursday, September 12th. Nine research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock presently has an average rating of Hold and an average price target of $10.26.

Tocagen (NASDAQ:TOCA) last posted its earnings results on Thursday, August 8th. The company reported ($0.72) earnings per share for the quarter, beating analysts consensus estimates of ($0.76) by $0.04. Tocagen had a negative net margin of 300.42% and a negative return on equity of 115.81%. The firm had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.50 million. As a group, sell-side analysts expect that Tocagen will post -2.64 earnings per share for the current fiscal year.

Several large investors have recently added to or reduced their stakes in TOCA. JPMorgan Chase & Co. raised its holdings in shares of Tocagen by 5.1% in the second quarter. JPMorgan Chase & Co. now owns 476,684 shares of the companys stock valued at $3,074,000 after acquiring an additional 23,293 shares in the last quarter. Acadian Asset Management LLC grew its stake in shares of Tocagen by 151.0% during the second quarter. Acadian Asset Management LLC now owns 92,450 shares of the companys stock worth $618,000 after acquiring an additional 55,621 shares during the last quarter. Rhumbline Advisers grew its stake in shares of Tocagen by 9.4% during the first quarter. Rhumbline Advisers now owns 25,491 shares of the companys stock worth $277,000 after acquiring an additional 2,188 shares during the last quarter. GSA Capital Partners LLP purchased a new stake in shares of Tocagen during the second quarter worth about $551,000. Finally, Sphera Funds Management LTD. purchased a new stake in shares of Tocagen during the first quarter worth about $1,304,000. Institutional investors and hedge funds own 35.38% of the companys stock.

About Tocagen

Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.

See Also: Momentum Indicators

Get a free copy of the Zacks research report on Tocagen (TOCA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.

The rest is here:
Tocagen (NASDAQ:TOCA) Upgraded to Buy by Zacks Investment Research - Mayfield Recorder

Recommendation and review posted by Bethany Smith

***The operating environment for global organizations is increasingly getting complex. This has left organizations playing catch-up with constantly emerging new business strategies. There is a growing demand for the inclusion of best-consulting services in sync with the organizations business strategy. The transformation of functional areas can and should be integrated into every industry. At Coherent Market Insights, we closely interact with our clients to meticulously examine their business consulting needs and accordingly offer tailored solutions through our unmatched business insights and analytics. ***

Coherent Market Insightsnow offers a detailed analysis of theHemophilia Gene Therapy Marketin new research that provides valuable business insights including revenue share, market valuation, and regional spectrum of this vertical. The report is an all-inclusive study of the current market trends, potential drivers and challenges, application landscape, competition situation, and industry-popular growth strategies, which will empower stakeholders to obtain a clear understanding of this domain. This report also provides precise information pertaining to market size, commercialization aspects and revenue estimation of this business. The report further elucidates the status of leading industry players thriving in the competitive spectrum of the Hemophilia Gene Therapy Market.

The PDF for the study can be requested using the following link: https://www.coherentmarketinsights.com/insight/request-pdf/2480

The latest study on Hemophilia Gene Therapy Market is a compilation of in-depth dissection of this business vertical that is projected to attain commendable proceeds during the estimated timeline, recording momentous yearly growth rate through the anticipated duration. The study precisely inspects the Hemophilia Gene Therapy Market and in doing so, it dispenses valuable insights with respect to industry size, revenue approximations, sales capacity, and more. Additionally, the report also examines the segments alongside the driving forces behind the commercialization portfolio of this business.

Overview

Hemophilia is a genetic bleeding disorder in which an individual lacks or has low levels of proteins called clotting factors. There are around 13 types of clotting factors that work with blood platelets, which are necessary for clotting process to initiate. There are three forms of hemophilia A, B, and C. Hemophilia A is the most common form and is caused due to deficiency in clotting factor VIII. Hemophilia B occurs due to deficiency of clotting factor IX and Hemophilia C is caused due to clotting factor XI deficiency. Hemophilia is incurable with current therapeutic options, which only reduces symptoms such as spontaneous bleeding in muscles and joints as well as increased risk for intracranial hemorrhage. These treatment options lasts only for a day and is costly. As against conventional clotting factor replacement therapy, gene therapy is expected to offer sustainable cure for hemophilia by correcting defective gene sequence (F8 or F9 gene) that codes for clotting factor VIII or IX in the patients body.

One of the key factors that make this report worth a purchase is the extensive outline it presents, pertaining to the competitive landscape of the industry. The study, on the basis of the competitive landscape, segments the market into the companies such asBioMarin Pharmaceuticals, Inc., Spark Therapeutics, Pfizer, Inc., UniQure NV, Ultragenyx Pharmaceutical, Shire PLC Sangamo Therapeutics, Inc., and Freeline Therapeutics.. These firms, as is observed, consistently vie with one another in order to accomplish a successful position in the industry.

The key region covered in this report are:

North America:United States, Canada, Mexico

Europe:Germany, France, UK, Russia, Italy, Rest of Europe

Middle East Africa:Turkey, Egypt, South Africa, GCC Countries, Rest of Middle East & Africa

Asia-Pacific:China, India, Australia, Japan, South Korea, Indonesia, Malaysia, Philippines, Thailand, Vietnam

A brief outline of the Hemophilia Gene Therapy Market scope:

Additional key understandings mentioned in the report have been listed below:

If you wish to find more details of the report or want customization, contact us. You can get a detailed of the entire research here. If you have any special requirements, please let us know and we will offer you the report as you want.

We Offer Customized Report, Click @ https://www.coherentmarketinsights.com/insight/request-customization/2480

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Read more:
Comprehensive Study on Global Hemophilia Gene Therapy Market 20182026 - Coherent Magazine

Recommendation and review posted by Bethany Smith

Axovant Gene Therapies Ltd (NASDAQ:AXGT) was the recipient of a significant drop in short interest during the month of August. As of August 15th, there was short interest totalling 1,061,600 shares, a drop of 17.1% from the July 15th total of 1,280,600 shares. Currently, 2.2% of the shares of the company are short sold. Based on an average trading volume of 662,600 shares, the short-interest ratio is presently 1.6 days.

Shares of Axovant Gene Therapies stock traded down $0.23 during trading on Wednesday, hitting $7.63. The companys stock had a trading volume of 78,183 shares, compared to its average volume of 386,879. The stock has a market cap of $178.68 million, a price-to-earnings ratio of -0.95 and a beta of 1.26. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.70 and a quick ratio of 1.70. Axovant Gene Therapies has a 52 week low of $3.81 and a 52 week high of $20.80. The stock has a 50-day moving average price of $6.87 and a two-hundred day moving average price of $4.87.

Axovant Gene Therapies (NASDAQ:AXGT) last released its earnings results on Friday, August 9th. The company reported ($1.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.34) by $0.11. On average, equities analysts predict that Axovant Gene Therapies will post -4.25 EPS for the current fiscal year.

AXGT has been the subject of a number of analyst reports. Cowen reiterated a hold rating on shares of Axovant Gene Therapies in a research report on Tuesday, July 9th. JMP Securities boosted their price objective on shares of Axovant Gene Therapies from $8.00 to $28.00 and gave the company an outperform rating in a research report on Thursday, June 6th. Zacks Investment Research downgraded shares of Axovant Gene Therapies from a buy rating to a hold rating in a research report on Wednesday, August 14th. ValuEngine upgraded shares of Axovant Gene Therapies from a sell rating to a hold rating in a research report on Thursday, August 1st. Finally, Svb Leerink started coverage on shares of Axovant Gene Therapies in a research report on Friday, June 21st. They set an outperform rating and a $18.00 price objective for the company. Three research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the companys stock. The company presently has an average rating of Buy and an average target price of $26.79.

Several hedge funds and other institutional investors have recently made changes to their positions in AXGT. Primecap Management Co. CA acquired a new position in shares of Axovant Gene Therapies during the first quarter valued at about $1,400,000. Marshall Wace LLP acquired a new position in shares of Axovant Gene Therapies during the first quarter valued at about $272,000. Sphera Funds Management LTD. acquired a new position in shares of Axovant Gene Therapies during the first quarter valued at about $6,794,000. BlackRock Inc. acquired a new position in shares of Axovant Gene Therapies during the second quarter valued at about $1,482,000. Finally, Tower Research Capital LLC TRC raised its holdings in shares of Axovant Gene Therapies by 955.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,221 shares of the companys stock worth $27,000 after acquiring an additional 3,821 shares during the last quarter. Hedge funds and other institutional investors own 13.48% of the companys stock.

Axovant Gene Therapies Company Profile

Axovant Gene Therapies Ltd., a clinical-stage gene therapy company, focuses on developing a pipeline of product candidates for debilitating neurological and neuromuscular diseases. The company's current pipeline of gene therapy candidates targets GM1 gangliosidosis, GM2 gangliosidosis, Parkinson's disease, oculopharyngeal muscular dystrophy, amyotrophic lateral sclerosis, and frontotemporal dementia.

Featured Story: Earnings Reports

Receive News & Ratings for Axovant Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.

Read this article:
Axovant Gene Therapies Ltd (NASDAQ:AXGT) Sees Large Decrease in Short Interest - TechNewsObserver

Recommendation and review posted by Bethany Smith

Global Gene Therapy Market 2019-2025 report is an in-depth study of Gene Therapy industry Size, Share, Trends and Analysis. It gets to the details of the competitive industry structure around the world. The worldwide Gene Therapy market report study, composed of competent standardized instruments such as S.W.O.T Analysis, offers a comprehensive assessment of the worldwide Gene Therapy market.

Gene Therapy business report offers a full percentage estimate of the CAGR of the period in question that will guide consumers to make choices based on the graph.

The study also covers the main players

Novartis, Kite Pharma, Inc., GlaxoSmithKline PLC, Spark Therapeutics Inc., Bluebird bio Inc.

who leads the worldwide Gene Therapy market.

The experts have calculated the size of the global Gene Therapy market on the basis of 2 major aspects: 1) Income and 2) Production Volume. The subtle analysis of the key chunks of the Gene Therapy market and their geographical diversification all the world has also been carried out. Numerous properties of global Gene Therapy market like upcoming aspects and growth factors related to every segment of the report have been put up thoroughly.

by Vector Type (Viral Vector and Non-viral Vector), Gene Type (Antigen, Cytokine, Tumor Suppressor, Suicide, Deficiency, Growth Factors, Receptors, and Others), and Applications (Oncological Disorders, Rare Diseases, Cardiovascular Diseases, Neurological Disorders, Infectious Disease, and Other Diseases) Analysis and Industry Forecast till 2025

Sample PDF Download Link: https://www.quintagoinsights.com/global-gene-therapy-market/request-sample/426

The worldwide Gene Therapy market study includes every feature of the worldwide Gene Therapy market right from basic market data to that of multiple significant criteria based on which the worldwide Gene Therapy market was diversified.

Gene Therapy industry research report includes a thorough assessment of present policies, rules, and rules along with the worldwide industry chain. Other than that, the worldwide Gene Therapy market report study also covers variables such as the manufacturing chain, top manufacturers, supply as well as demand for those products along with the price structure as well as income.

Also calculated in the global Gene Therapy market research report is the different properties of supply and demand, the chronological presentation, manufacturing capacity along with the detailed analysis of the global Gene Therapy market.

1. To evaluate the status of worldwide Gene Therapy, future forecasts, opportunities for development, key markets, and important players.

2. To present the growth of Gene Therapy in the U.S., Europe, and China.

3. To profile key players strategically and analyze their development plan and strategies comprehensively.

4. Defining, describing and forecasting the market by type of item, market and main areas.

Inquire about the report here: https://www.quintagoinsights.com/global-gene-therapy-market/enquiry-before-buy/426

In the end, as trading experts across the value chain, our panel of trading experts have made extensive attempts to do this group action and heavy-lifting add order to generate important players with helpful main & secondary information on the world electricity sub metering market for Gene Therapy. Furthermore, the study includes inputs from our trade advisors which can make it easier for important players to save half their time from the internal assessment. Companies Who receive and use this report will benefit fully from the inferences contained in it. With the exception of this, the study also offers an in-depth assessment of Gene Therapy.

Get in Touch with Us :

F- A/104,Sai Atharva Apartment,Near Swaraj Garden,Pimple Saudagar, Pune, IndiaMail: sales@researchandreports.biz

John is the chief editor of News Conduct. He also handles other important responsibilities like advertisements, comment handling, newsletter subscription and much more. John loves art and he is a screenwriter and playwright.

Continued here:
Global Gene Therapy Market Analysis Key Players Opportunities Segmentation and Forecast to 2025 - News Conduct - News Conduct

Recommendation and review posted by Bethany Smith

Axovant Gene Therapies Ltd (NASDAQ:AXGT) was the recipient of a significant drop in short interest during the month of August. As of August 15th, there was short interest totalling 1,061,600 shares, a drop of 17.1% from the July 15th total of 1,280,600 shares. Currently, 2.2% of the shares of the company are short sold. Based on an average trading volume of 662,600 shares, the short-interest ratio is presently 1.6 days.

Shares of NASDAQ AXGT traded down $0.23 during trading on Wednesday, hitting $7.63. 78,183 shares of the company traded hands, compared to its average volume of 386,879. The businesss fifty day moving average is $6.87 and its 200 day moving average is $4.87. Axovant Gene Therapies has a fifty-two week low of $3.81 and a fifty-two week high of $20.80. The firm has a market capitalization of $178.68 million, a price-to-earnings ratio of -0.95 and a beta of 1.26. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.70 and a current ratio of 1.70.

Axovant Gene Therapies (NASDAQ:AXGT) last announced its quarterly earnings data on Friday, August 9th. The company reported ($1.23) earnings per share for the quarter, beating the consensus estimate of ($1.34) by $0.11. On average, analysts predict that Axovant Gene Therapies will post -4.25 EPS for the current year.

Several institutional investors and hedge funds have recently bought and sold shares of AXGT. Sphera Funds Management LTD. acquired a new stake in shares of Axovant Gene Therapies in the 1st quarter worth about $6,794,000. Primecap Management Co. CA acquired a new stake in shares of Axovant Gene Therapies in the 1st quarter worth about $1,400,000. BlackRock Inc. acquired a new stake in shares of Axovant Gene Therapies in the 2nd quarter worth about $1,482,000. Marshall Wace LLP acquired a new stake in shares of Axovant Gene Therapies in the 1st quarter worth about $272,000. Finally, Jane Street Group LLC raised its holdings in shares of Axovant Gene Therapies by 28.8% in the 2nd quarter. Jane Street Group LLC now owns 46,455 shares of the companys stock worth $289,000 after acquiring an additional 10,375 shares during the last quarter. Institutional investors own 13.48% of the companys stock.

Axovant Gene Therapies Company Profile

Axovant Gene Therapies Ltd., a clinical-stage gene therapy company, focuses on developing a pipeline of product candidates for debilitating neurological and neuromuscular diseases. The company's current pipeline of gene therapy candidates targets GM1 gangliosidosis, GM2 gangliosidosis, Parkinson's disease, oculopharyngeal muscular dystrophy, amyotrophic lateral sclerosis, and frontotemporal dementia.

Featured Story: Earnings Reports

Receive News & Ratings for Axovant Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.

Here is the original post:
Axovant Gene Therapies Ltd (NASDAQ:AXGT) Short Interest Update - Tech Know Bits

Recommendation and review posted by Bethany Smith

Regenxbio (NASDAQ:RGNX) was downgraded by Zacks Investment Research from a hold rating to a sell rating in a research note issued on Thursday, Zacks.com reports.

According to Zacks, REGENXBIO Inc. is a biotechnology company. The Company focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Its products candidates include RGX-501, for the treatment of homozygous familial hypercholesterolemia which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; RGX-111, for the treatment of Mucopolysaccharidosis Type I which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system; RGX-121, for the treatment of Mucopolysaccharidosis Type II; RGX-314, for the treatment of wet age-related macular degeneration and RGX-321, for the treatment of X-linked retinitis pigmentosa. REGENXBIO Inc. is headquartered in Rockville, Maryland.

A number of other brokerages have also issued reports on RGNX. Svb Leerink upgraded shares of Regenxbio from an underperform rating to a market perform rating and decreased their target price for the stock from $38.00 to $37.00 in a research report on Tuesday, August 20th. ValuEngine upgraded shares of Regenxbio from a buy rating to a strong-buy rating in a research report on Thursday, August 1st. Leerink Swann upgraded shares of Regenxbio from an underperform rating to a market perform rating in a research report on Tuesday, August 20th. They noted that the move was a valuation call. BidaskClub upgraded shares of Regenxbio from a strong sell rating to a sell rating in a research report on Thursday, September 12th. Finally, Raymond James initiated coverage on shares of Regenxbio in a research report on Thursday, June 13th. They set an outperform rating on the stock. Two analysts have rated the stock with a sell rating, three have issued a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. Regenxbio currently has a consensus rating of Hold and a consensus target price of $79.56.

Regenxbio (NASDAQ:RGNX) last announced its earnings results on Wednesday, August 7th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, topping the Zacks consensus estimate of ($0.50) by $0.46. Regenxbio had a negative net margin of 88.57% and a negative return on equity of 15.39%. The firm had revenue of $7.88 million for the quarter, compared to analyst estimates of $5.45 million. During the same quarter last year, the business earned $0.30 earnings per share. Regenxbios revenue was down 80.3% compared to the same quarter last year. As a group, equities analysts predict that Regenxbio will post -2.85 EPS for the current year.

In other Regenxbio news, insider Kenneth T. Mills sold 15,000 shares of Regenxbio stock in a transaction on Friday, July 19th. The shares were sold at an average price of $49.49, for a total value of $742,350.00. Following the transaction, the insider now owns 261,000 shares in the company, valued at approximately $12,916,890. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Patrick J. Christmas sold 5,486 shares of the firms stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $42.00, for a total transaction of $230,412.00. Following the completion of the transaction, the senior vice president now directly owns 8,058 shares in the company, valued at approximately $338,436. The disclosure for this sale can be found here. In the last quarter, insiders sold 40,486 shares of company stock worth $1,786,162. 13.80% of the stock is owned by company insiders.

Several hedge funds have recently modified their holdings of the company. BlackRock Inc. raised its stake in shares of Regenxbio by 3.5% in the 2nd quarter. BlackRock Inc. now owns 5,047,103 shares of the biotechnology companys stock valued at $259,270,000 after acquiring an additional 169,888 shares during the period. Royal Bank of Canada raised its stake in shares of Regenxbio by 36.2% in the 2nd quarter. Royal Bank of Canada now owns 3,910 shares of the biotechnology companys stock valued at $201,000 after acquiring an additional 1,040 shares during the period. UBS Group AG raised its stake in shares of Regenxbio by 438.6% in the 2nd quarter. UBS Group AG now owns 263,094 shares of the biotechnology companys stock valued at $13,515,000 after acquiring an additional 214,244 shares during the period. Nuveen Asset Management LLC purchased a new position in shares of Regenxbio in the 2nd quarter valued at $10,206,000. Finally, UBS Asset Management Americas Inc. raised its stake in shares of Regenxbio by 0.6% in the 2nd quarter. UBS Asset Management Americas Inc. now owns 119,714 shares of the biotechnology companys stock valued at $6,150,000 after acquiring an additional 752 shares during the period. 79.40% of the stock is currently owned by institutional investors and hedge funds.

About Regenxbio

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.

Featured Article: What is the accumulation/distribution indicator?

Get a free copy of the Zacks research report on Regenxbio (RGNX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.

Read this article:
Regenxbio (NASDAQ:RGNX) Downgraded by Zacks Investment Research to Sell - Mayfield Recorder

Recommendation and review posted by Bethany Smith

The report titled,Global Gene Therapy Market Professional Insight Survey and Forecast to 2028is recently generated by MarketResearch.biz. This research study includes the investigations done of the past progress, present ongoing market scenarios, and future prospects. The report analysis of Gene Therapy incorporates market size & share, upstream circumstance, in detail segmentation outlook, price & cost, and industry environment. It starts from the overview of industry chain structure and depicts the upstream. Besides, the report examinations market size and estimate in different geographies, type, and end-use segment, in addition, the report presents market competition overview among the major organizations and companies profiles, besides, market price and channel highlights are covered in the report.

This statistical surveying research report deals with the present scenario of the market. This investigation report summarizes the technologies, which can help to scale up the growth of the businesses in the near future and obtainable in a clear and professional manner with effective infographics. It clarifies a thorough synopsis of Gene Therapy market dependent on the central parameters. merchandises, End users, provinces and many other subdivisions are planned and elucidated. A transitory idea about the dynamic forces which help make the market more prosperous is deliberated in order to help customer appreciate the future market situation.

Prominent Top Key Vendors of Gene Therapy Report:-Novartis, Kite Pharma Inc, GlaxoSmithKline PLC, Spark Therapeutics Inc, Bluebird bio Inc, Genethon, Transgene SA, Applied Genetic Technologies Corporation, Oxford BioMedica PLC, NewLink Genetics Corp., Amgen Inc

Looking for more information on this Research Study? Click Here @https://marketresearch.biz/report/gene-therapy-market/request-sample

Objectives of theGene TherapyStudy:

Identification and measurement of global and enzymatic and reactive universal enzymes based on end-user, product, key application, and geometric region.

To identify the key micro-energy markets and their drivers in the Global Micro Enzymes market and their buyers and reagents, which are expected to provide growth opportunities in the coming years.

Identify market participants and opportunities for market participants and access payment details for major market leaders.

For detailed information about the key factors affecting market growth (drivers, restraints, issues, and opportunities).

For the four main areas, notably, North America (United States, Canada)), Europe (Germany, Spain, France, UK, Russia, and Italy), Asia-Pacific (China, Japan, India, Australia, and South Korea), and the rest (of Latin America and the Middle East & Africa).

To analyze the market structure and the key players involved in the Global Enzymes market and their buyers and reagents in the market and to evaluate in detail their key competencies.

To track and analyze the competitive landscape such as market sharing research and competitive leadership.

For the successful business viewpoint, the market study also examines different worldwide areas, for example, North America, Latin America, Asia-Pacific, Europe, The Middle East, and Africa by considering various segments for example vector type, gene type, application, and region. SWOT and Porters five analysis are also successfully discussed to analyze informative data such as cost, prices, revenue, and end-users. Gene Therapy research report has been evaluated base on various attributes such as manufacturing base, products or services and raw material to comprehend the necessities of the organizations. Apart from the regional outlook, the report also draws attention to leading industry key players to know the successful sales strategies of the businesses. Gene Therapy report can effectively help companies and decision-makers in addressing these challenges strategically to gain the maximum benefits in the highly competitive Gene Therapy Market.

Gene Therapy Market Segmentation byvector type, gene type, application, and region:-

By Vector:Viral vectorRetrovirusesLentivirusesAdenovirusesAdeno Associated VirusHerpes Simplex VirusPoxvirusVaccinia VirusNon-viral vectorNaked/Plasmid VectorsGene GunElectroporationLipofection

By Gene Therapy:AntigenCytokineTumor SuppressorSuicideDeficiencyGrowth factorsReceptorsOther

By Application:Oncological DisordersRare DiseasesCardiovascular DiseasesNeurological DisordersInfectious diseaseOther Diseases

Fill Free with your Queries to Get a Call From Our Industry Expert @https://marketresearch.biz/report/gene-therapy-market/#inquiry

Gene Therapy MarketTable Of Content Overview:

1 INTRODUCTION

1.1 Study Deliverables

1.2 Study Assumptions

1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Overview

4.2 Introduction to Market Drivers & Restraints

4.3 Market Drivers

4.3.1 Rising Adoption of Mega Data Centers

4.3.2 Rising Adoption of Cloud Computing

4.4 Market Restraints

4.4.1 High Initial Investment

4.5 Industry Attractiveness Porters Five Force Analysis

4.5.1 Threat of New Entrants

4.5.2 Bargaining Power of Buyers/Consumers

4.5.3 Bargaining Power of Suppliers

4.5.4 Threat of Substitute Products

4.5.5 Intensity of Competitive Rivalry

5 TECHNOLOGY SNAPSHOT

6 MARKET SEGMENTATION

6.1 By Type

6.1.1 Solutions

6.1.1.1 Power Distribution Unit

6.1.1.2 UPS

6.1.1.3 Busway

6.1.1.4 Other Solutions

6.1.2 Services

6.1.2.1 Consulting

6.1.2.2 System Integration

6.1.2.3 Professional Service

6.2 By End-user Application

6.2.1 Information Technology

6.2.2 Manufacturing

6.2.3 BFSI

6.2.4 Government

6.2.5 Energy

6.2.6 Other End-user Applications

6.3 Geography

6.3.1 North America

6.3.2 Europe

6.3.3 Asia-Pacific

6.3.4 Latin America

6.3.5 the Middle East & Africa

7 COMPETITIVE LANDSCAPE

7.1 Company Profiles

8 INVESTMENT ANALYSIS

9 MARKET OPPORTUNITIES AND FUTURE TRENDS

For Information of Multiple Category related Research Report, Visit @https://marketresearch.biz/categories/

About us:

Marketresearch.biz is a specialized market research, analytics, and solutions company, offering strategic and tactical support to clients for making well-informed business decisions. We are a team of dedicated and impassioned individuals, who believe strongly in giving our very best to what we do and we never back down from any challenge.

Get in touch with us:

Mr. Benni Johnson

MarketResearch.Biz (Powered By Prudour Pvt. Ltd.)

420 Lexington Avenue, Suite 300, New York City, NY 10170, United States

Tel: +1 347 826 1876

Email:inquiry@marketresearch.biz

Originally posted here:
New Edition 2019-2028: Global Gene Therapy Market Insight Inflation & Massive Growth - Market News Live

Recommendation and review posted by Bethany Smith

Cat owners and enthusiasts have heard a number of fascinating myths about male calico cats. While they are relatively rare, with an estimated one male in 3,000 calico cat births, there is no extraordinary demand for them. They do not make good breeding studs because almost all male calicos are sterile. In fact, only about one in 10,000 male calicos is fertile.

Some people have the misconception that calico kittens and cats comprise a specific cat breed. However, calico is the description of a cat's coloration. Cats of many breeds can be a calico, or true tricolor, as a result of their genetic heritage.

Unlike cats with tortoiseshell coloring, the coats of calico cats are of three distinct colors - red, black and white, or a variation of those colors.

Male calicos are a genetic anomaly. Cats, like humans, have two sex chromosomes. Chromosomes carry genes and determine an animal's traits. The required red color for a calico cat is passed only on a female (X) chromosome. How then can a male cat inherit the red colored required for a calico cat?

To put it simply, two chromosomes determine gender. Each parent contributes one chromosome to the offspring. The mother, who has only X chromosomes, always contributes an X chromosome. The father who has both X and Y chromosomes, can contribute either an X or a Y chromosome to his offspring. Thus, it is the father who determines the sexes of his kittens. The red color gene cannot be passed to a male offspring due to unusual characteristics of the gene in question. Under certain conditions, when the red genes are passed to a female offspring, she displays not the expected red or orange coat, but the tricolor coat of a true calico cat.

How then can a male be a true calico? Sometimes there is an incomplete division of the chromosome pair when the chromosomes are separating at the time of fertilization. When that happens, the incomplete chromosome ends up attached to another of the two required chromosomes, giving the offspring one of the following combinations:

In both cases, the result is a male cat who can inherit the trait for a true calico coat. Among humans, this genetic arrangement is called Klinefelter syndrome. A male calico usually cannot sire offspring because the genetics described above almost always guarantees that he will be sterile.

One might suppose that male calicos would bring a high price among breeders because of their rarity. You may even see some websites claiming a purebred male calico cat can fetch a price as high as $1,000 to $2,000. The truth is, while they are an interesting phenomenon, they are of little interest to breeders because they are sterile. It's possible a pet owner might want to pay that amount of money to own a cat that's a rarity, but chances are if you're looking to buy a male calico cat don't expect to pay much more than you would for any regular unpedigreed house cat.

Although most male calicos are sterile, it is a good idea to neuter them to deter spraying and other unwelcome male behaviors. Despite their limitations, they are still boys at heart!

As mentioned earlier, male calico cats have distinctive tricolor coats, but they are not a separate breed. In fact, as many as 16 different cat breeds can have calico coloration, and male calicos can occur among any of those breeds. Some common breeds that may have calico coloration are:

Male calico cats are the offspring with a genetic anomaly of parents representing many possible cat breeds. While female calico cats are quite common, true male calicos are rare and of particular interest for the combination of their unique coloration and sex. While it's a myth that they can command a high price among cat fanciers, if you happen to own a male calico, you can treasure him for his rare condition and other wonderful feline attributes!

Excerpt from:
Myths and Facts About Male Calico Cats | LoveToKnow

Recommendation and review posted by Bethany Smith

Science and technology are often considered to be the forte of men. Nevertheless, the contribution of women to the progress of these areas cannot be disregarded. There have been numerous gifted and far-famed women scientists in history who made crucial discoveries and inventions in the world of science.

Today on our Science Blog, well take a look at some of the most famous women scientists and their achievements.

Polish-born French physicist and chemist best known for her contributions to radioactivity.

British primatologist and ethologist, widely considered to be the worlds foremost expert on chimpanzees.

Advertisements

German-born American physicist who received Nobel Prize for suggesting the nuclear shell model of the atomic nucleus.

American marine biologist and conservationist whose work revolutionzied the global environmental movement.

British biophysicist best known for her work on the molecular structures of coal and graphite, and X-ray diffraction.

American scientist and cytogeneticist who received Nobel Prize in 1983 for the discovery of genetic transposition.

Italian neurologist who received Nobel Prize in 1986 for the discovery of Nerve growth factor (NGF).

American biochemist and pharmacologist who received the 1988 Nobel Prize in Physiology or Medicine.

American physician who was the first woman to become a medical doctor in the United States.

German biologist who received the Albert Lasker Award for Basic Medical Research in 1991.

Advertisements

More:
10 Famous Women Scientists in History

Recommendation and review posted by Bethany Smith